Table 2 Clinical features of LC patients by HR type HPV DNA status and p16 immunohistochemistry
From: High-risk type human papillomavirus infection and p16 expression in laryngeal cancer
All cases (n = 88) | HR-HPV (+) (n = 16) | HR-HPV−/p16 - (n = 72) | |||
|---|---|---|---|---|---|
HR-HPV+/p16+ (n = 5) | HR-HPV+/p16- (n = 11) | ||||
Sex | |||||
Male | 82 | 16 | 5 | 11 | 66 |
Female | 6 | 0 | 0 | 0 | 6 |
Age (years) | |||||
< 66 | 39 | 9 | 4 | 5 | 30 |
≥ 66 | 49 | 7 | 1 | 6 | 42 |
T | |||||
T1, T2 | 63 | 11 | 3 | 8 | 52 |
T3, T4 | 25 | 5 | 2 | 3 | 20 |
N | |||||
N0, N1 | 77 | 14 | 4 | 10 | 63 |
N2, N3 | 11 | 2 | 1 | 1 | 9 |
Tumor subsite | |||||
Supraglottis | 22 | 3 | 1 | 2 | 19 |
Glottis | 59 | 12 | 4 | 8 | 47 |
Subglottis | 7 | 1 | 0 | 1 | 6 |
Stage | |||||
I, II | 59 | 11 | 1 | 8 | 48 |
III, IV | 29 | 5 | 2 | 3 | 24 |
Smoking habit (pack years) | |||||
< 40 | 39 | 10 | 3 | 6 | 29 |
≥ 40 | 49 | 6 | 0 | 5 | 43 |
Alcohol consumption (g/day) | |||||
< 40 | 50 | 9 | 3 | 5 | 41 |
≥ 40 | 38 | 7 | 0 | 6 | 31 |
Primary treatment | |||||
Surgery±RT/CCRT CCRT to Surgery | 40 | 6 | 2 | 4 | 34 |
RT or CCRT | 48 | 10 | 1 | 7 | 38 |
5-year cumulative survival (%) | 80.7 | 87.5 | 100 | 81.8 | 79.5 |